PC
UTHR icon

PointState Capital’s United Therapeutics UTHR Stock Holding History

PointState Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-275,000
Closed -$47.8M – 142
2015
Q2 		$47.8M Sell
275,000
-116,600
-30% -$21M 0.56% 40
2015
Q1 		$67.5M Buy
+391,600
New +$59.7M 0.91% 30

Other funds holding UTHR

ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PointState Capital's UTHR Position: Q3 2015 in Review

PointState Capital sold out of United Therapeutics (UTHR) in Q3 2015, closing a stake of 275,000 shares — an estimated $47.8M sold.

PointState Capital first reported a position in UTHR in Q1 2015 and held it in 2 quarters. The position peaked at $67.5M in Q1 2015. 372 funds tracked by Wall St. Rank hold UTHR as of Q3 2015.

  • PointState Capital reported no remaining United Therapeutics position as of Q3 2015 after selling out during the quarter.
  • PointState Capital sold 275,000 United Therapeutics shares in Q3 2015, an estimated $47.8M.
  • PointState Capital first reported a position in United Therapeutics in Q1 2015 and held it in 2 quarters.
  • PointState Capital's United Therapeutics position peaked at $67.5M in Q1 2015.
  • 372 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2015.

Based on PointState Capital's 13F filing for Q3 2015, filed 16 Nov 2015.